Innate Pharma S.A. announced that IPH 2101 (NN 1975), developed by Novo Nordisk A/S in collaboration with the Company, was administered for the first time in patients suffering from multiple myeloma.
| PR in english | 57.57 KB |
| CP en français | 42.36 KB |
Innate Pharma S.A. announced that IPH 2101 (NN 1975), developed by Novo Nordisk A/S in collaboration with the Company, was administered for the first time in patients suffering from multiple myeloma.
| PR in english | 57.57 KB |
| CP en français | 42.36 KB |